Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
The deproteinized samples were incubated with necessary reaction components for 30 min at room temperature protected from light
(approx 5-10 sesiones)
Quick disclosure - as a pharmaceutical and biotech equity research analyst at one of the largest banks for the past 5 years, I spent lots of time analyzing one of the two companies mentioned above, which means I was partly responsible for our teams view of which pharma companies presented a good investment opportunity for institutional investors who were our clients and had access to our research
US$ 23.73
US$ 21.47
US$ 24.49
US$ 21.30
